Mitochondria sit at the crossroads of nearly every process that determines whether a tumor thrives or dies, from energy production and cell death to immune surveillance and drug resistance. Far from being passive power plants, these organelles actively reshape cancer biology by altering their own metabolism, generating chemical signals that drive metastasis, and even moving between cells to spread their influence. At the same time, the immune system relies on healthy mitochondrial function to mount effective antitumor responses, and tumors exploit mitochondrial dysfunction in immune cells as a way to evade destruction. Understanding these dual roles is reshaping how researchers think about both cancer progression and emerging treatments.
How Cancer Cells Rewire Mitochondrial Metabolism
For decades, the prevailing view held that cancer cells primarily rely on a sugar-burning shortcut to generate energy, even when oxygen is available. That shortcut is real, but the picture has turned out to be far more nuanced. A subset of cancer cells, particularly cancer stem cells, actually depend heavily on the mitochondrial energy-production system for survival. Cancer stem cells are the small population within a tumor thought to seed new growth, resist chemotherapy, and drive relapse. Multiple studies have shown that these cells ramp up mitochondrial energy output, running their electron transport chains harder than the bulk of the tumor does.1PubMed Central. Role of Mitochondria in Cancer Stem Cell Resistance Research on aggressive breast cancers found that the cancer stem cell fraction had higher respiratory capacity, elevated membrane potential in their mitochondria, and increased production of reactive oxygen species compared to non-stem cancer cells, all signs of a hyperactive mitochondrial engine.2Cell Metabolism. MYC and MCL1 Cooperatively Promote a Mitochondrial Oxidative Phosphorylation Program to Induce Cancer Stem Cells in Resistant Tumor
This metabolic preference has direct implications for treatment. Resistant cancer cells, especially cancer stem cells, depend on this mitochondrial energy pathway to survive exposure to anticancer drugs. Inhibiting that pathway can selectively kill them.3PubMed Central. The Effect of Oxidative Phosphorylation on Cancer Drug Resistance The takeaway is that the old “cancer cells just love sugar” narrative misses an entire survival strategy that the most dangerous tumor cells use.
Oncometabolites and Epigenetic Hijacking
Mitochondria house a central metabolic cycle that breaks down nutrients and feeds electrons into the energy chain. When mutations hit enzymes in this cycle, abnormal byproducts accumulate. Three of the best-characterized are 2-hydroxyglutarate, succinate, and fumarate. These molecules, collectively called oncometabolites, interfere with enzymes that normally help regulate gene expression by modifying DNA and the proteins that package it.4PubMed Central. TCA cycle-derived oncometabolites in cancer and the immune microenvironment The result is widespread changes in which genes get turned on or off, pushing cells toward uncontrolled growth and helping tumors evade the immune system.
By blocking the enzymes that remove chemical marks from DNA, oncometabolites effectively lock cells into a pro-cancer gene expression pattern. They also interfere with a cell’s ability to sense oxygen levels properly, mimicking a low-oxygen state that triggers blood vessel growth and other survival programs.5PubMed Central. Metabolic Rewiring and the Characterization of Oncometabolites Because these effects cascade from a single metabolic defect into dozens of downstream changes, oncometabolites act as amplifiers of cancer’s progression.
Reactive Oxygen Species and the Spread of Cancer
Mitochondria are the main source of reactive oxygen species in cells. At low levels, these molecules serve as useful signals. At high levels, they damage DNA and proteins. Cancer cells exploit the middle ground, using moderately elevated reactive oxygen species to activate programs that promote invasion and metastasis. The key intermediary in many cancers is a protein called HIF-1α, which normally accumulates only when oxygen is scarce. Mitochondrial reactive oxygen species can stabilize HIF-1α even when oxygen levels are adequate, creating what researchers describe as a pseudohypoxic state.
In melanoma, this process has been studied in detail. One study showed that the electron transport chain in melanoma cells generates reactive oxygen species that stabilize HIF-1α, which then activates a signaling cascade promoting cell motility, invasion into surrounding tissue, and the formation of new blood-vessel-like structures.6PubMed. HIF-1α stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells More recent work confirmed that this pseudohypoxic stabilization of HIF-1α in melanoma is driven primarily by mitochondrial reactive oxygen species rather than actual low oxygen, and that specific changes in mitochondrial pore proteins can amplify the effect.7Signal Transduction and Targeted Therapy. Pseudohypoxic stabilization of HIF1α via cyclophilin D suppression promotes melanoma metastasis Similar findings have emerged in breast cancer, where mitochondrial dysfunction boosts reactive oxygen species, drives HIF-1α accumulation under normal oxygen conditions, and enhances cell migration and invasion.8PLOS ONE. Mitochondrial Dysfunction Promotes Breast Cancer Cell Migration and Invasion through HIF1α Accumulation via Increased Production of Reactive Oxygen Species
Cells also maintain an antioxidant defense system to counterbalance reactive oxygen species. In cancer, this defense system, governed by a protein called Nrf2, gets co-opted. In aggressive tumors like pancreatic cancer, Nrf2 shields cancer cells from a form of cell death called ferroptosis, which depends on iron-driven damage to cell membranes. By keeping mitochondrial reactive oxygen species in a survivable range while still allowing enough to activate pro-invasion signals, Nrf2 contributes to treatment resistance.9PubMed Central. The Role of Nrf2 in the Regulation of Mitochondrial Function and Ferroptosis in Pancreatic Cancer
How Tumors Dodge the Death Switch
Mitochondria are the executioners of programmed cell death. When a cell becomes damaged or receives the right internal signals, pro-death proteins in the BCL-2 family punch holes in the outer mitochondrial membrane. This event, called mitochondrial outer membrane permeabilization, releases a molecule called cytochrome c into the cell’s interior. Cytochrome c then triggers a chain reaction that dismantles the cell from the inside.10PubMed Central. Targeting BCL-2 regulated apoptosis in cancer
Cancer cells survive in part by tipping the balance in favor of anti-death BCL-2 proteins, which keep those membrane pores from forming. This is why drugs that block anti-death BCL-2 proteins have shown promise in blood cancers and are being studied in solid tumors. The logic is straightforward: if you remove the brakes on the death switch, the cell’s own mitochondria will do the killing.
Mitochondrial DNA as an Immune Alarm
Mitochondria carry their own small genome, a vestige of their ancient bacterial ancestry. When this DNA leaks out of mitochondria and into the cell’s interior, or is released outside the cell entirely, it trips an immune alarm system called the cGAS-STING pathway. This pathway normally detects foreign DNA from invading pathogens and triggers inflammation. Mitochondrial DNA activates the same response, stimulating the production of immune-signaling molecules that can recruit and activate immune cells against the tumor.11Biochimica et Biophysica Acta (BBA) – Reviews on Cancer. Mitochondrial DNA-activated cGAS-STING pathway in cancer: Mechanisms and therapeutic implications
Experimental work has confirmed this mechanistically. When mitochondrial DNA was introduced into immune suppressor cells in the lab, it activated the cGAS-STING pathway and triggered both interferon signaling and inflammatory gene expression. Cells lacking cGAS did not respond, confirming that the sensor is essential for reading the mitochondrial DNA alarm.12Immunity. Mitochondria Cancer: Pivotal Roles in Tumor Growth and Immunity Mitochondrial DNA also influences macrophages in the tumor environment, helping determine whether they adopt a tumor-fighting or tumor-promoting identity.13PubMed Central. Mitochondrial DNA on Tumor-Associated Macrophages Polarization and Immunity
What makes this story complicated is that mutations in mitochondrial DNA do not have a simple dose-response relationship with tumor growth. A study using breast cancer mouse models found that moderate levels of mitochondrial DNA mutations actually promoted larger tumors and more lung metastases. But mice carrying very high mutation loads had smaller tumors and fewer metastases than the moderately mutated group, suggesting that beyond a certain threshold, mitochondrial dysfunction tips from being cancer-promoting to cancer-impairing.14bioRxiv. MtDNA heteroplasmy controls tumor immune reprogramming through mitochondrial translation That sweet spot in between may partly explain why some tumors are highly aggressive while others with seemingly worse mitochondrial damage are not.
When the Immune System Runs Out of Fuel
The immune system’s ability to kill cancer cells depends on T cells that can sustain intense metabolic activity over prolonged battles inside tumors. Mitochondrial dysfunction in these T cells is a major driver of a state called exhaustion, where the cells lose their killing power and become functionally impaired. Defects in energy production, an inability to adapt to the metabolic demands of the tumor environment, and loss of mitochondrial membrane potential all contribute to this exhaustion.15PubMed Central. Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells
Tumors worsen this problem by creating a metabolically hostile environment. Glucose is scarce, and the tumor microenvironment is acidic and low in oxygen. Within this environment, regulatory T cells, a population of immune cells that suppress immune responses rather than activate them, gain a metabolic edge. Research in mouse models showed that tumor-infiltrating regulatory T cells accumulate fats inside themselves and rely on fatty acid production and burning for their energy needs. This dual strategy of using both sugar-based and fat-based fuel pathways gives regulatory T cells a proliferative advantage over the killer T cells that the immune system actually needs.16PubMed Central. Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth The net effect is that the tumor environment simultaneously starves its attackers and feeds its protectors, with mitochondrial metabolism at the center of both dynamics.
Mitochondria on the Move
One of the more surprising discoveries in recent years is that mitochondria can physically travel between cells in the tumor environment. Through thin membrane bridges called tunneling nanotubes, tumor cells share mitochondria with each other and with surrounding stromal cells, immune cells, and other neighbors. These transfers are not random. They can boost the recipient cell’s energy capacity, promote drug resistance, and help tumors evade immune detection.17PubMed Central. Mitochondrial transfer in tunneling nanotubes-a new target for cancer therapy
Mitochondria also constantly reshape themselves through fission and fusion, splitting apart and merging back together. These dynamics are not just housekeeping. The protein DRP1 drives mitochondrial fission and has been linked to breast cancer development, with research exploring whether it could serve as a therapeutic target.18PubMed Central. DRP1: shedding light on the complex nexus of mitochondrial fission and breast cancer Cells also use a quality-control process called mitophagy, in which damaged mitochondria are selectively digested and recycled. In tumors, mitophagy has been implicated in sustaining cell survival, promoting proliferation, and contributing to drug resistance in solid cancers.19PubMed Central. Mitophagy in the mechanisms of treatment resistance in solid tumors By clearing away their most damaged mitochondria, cancer cells keep their remaining organelles functional enough to power resistance to treatment.
Calcium Signals and Stress Responses Between Organelles
Mitochondria do not operate in isolation. They maintain physical contact points with the endoplasmic reticulum, the cell’s protein-folding and lipid-manufacturing network. These contact zones, known as mitochondria-associated membranes, create tiny pockets where calcium concentrations are much higher than in the rest of the cell. The pattern of calcium flow through these junctions determines whether a cell ramps up its energy production or triggers its own death. Steady, rhythmic pulses of calcium stimulate metabolism and promote survival. A sudden, massive calcium flood pushes the cell toward apoptosis.20PubMed Central. Emerging molecular mechanisms in chemotherapy: Ca2+ signaling at the mitochondria-associated endoplasmic reticulum membranes
In cancer, these contact zones are enriched with proteins that have tumor-promoting or tumor-suppressing functions, and disruptions to their structure have been linked to cancer onset, progression, and metastasis.21PubMed Central. Role of Mitochondria-Associated ER Membranes in Calcium Regulation in Cancer-Specific Settings Cancer cells that learn to fine-tune calcium transfer can keep their mitochondria energized without accidentally triggering the death cascade.
Beyond calcium crosstalk, mitochondria send distress signals back to the cell’s nucleus when their internal proteins begin to misfold under stress. This stress response, known as the mitochondrial unfolded protein response, triggers the production of protective chaperone proteins and enzymes that help restore mitochondrial function. Cancer cells hijack this system to repair damaged mitochondria and continue growing, invading, and metastasizing even under conditions that would normally be lethal.22PubMed Central. Insight into the mitochondrial unfolded protein response and cancer: opportunities and challenges
Why Tumors Bounce Back After Treatment
One of the most frustrating clinical realities is that tumors often respond to initial treatment and then return with renewed vigor. Mitochondrial metabolic flexibility is a major reason. When chemotherapy or targeted therapy cuts off a tumor’s preferred fuel supply, surviving cells rewire their metabolism. They shift away from sugar dependence and lean harder on mitochondrial energy production, burning fatty acids and the amino acid glutamine as alternative fuels.23PubMed Central. Targeting Metabolic Vulnerabilities to Combat Drug Resistance in Cancer Therapy
This metabolic switch is characteristic of drug-tolerant persister cells, a small population that enters a dormant-like state to survive treatment. These persisters abandon the fast-growing, sugar-hungry lifestyle of the bulk tumor and adopt a quieter phenotype that depends on mitochondrial energy production and fatty acid burning.24PubMed Central. Tumor metabolic plasticity in therapy resistance: from the Warburg effect to mitochondrial hijacking Once the treatment pressure eases, these persister cells can re-expand and seed a resistant tumor. The implication is clear: targeting the tumor’s sugar metabolism alone leaves the mitochondrial escape route wide open.
Targeting Mitochondria as a Therapeutic Strategy
Given how central mitochondria are to tumor survival and immune evasion, researchers have been developing drugs that attack mitochondrial function directly. One approach involves inhibiting complex I, the first major step in the mitochondrial electron transport chain. The diabetes drug metformin has mild complex I inhibitory activity, which is one reason it has attracted attention as a potential cancer-prevention agent. More potent complex I inhibitors have been tested in laboratory and animal models. One such compound suppressed tumor growth in mouse models by altering the acid balance inside and outside cancer cells, a mechanism that operates independently of simply starving cells of energy.25PubMed Central. Mitochondrial complex I inhibitors suppress tumor growth through concomitant acidification of the intra- and extracellular environment Another complex I inhibitor, BAY 87-2243, significantly reduced tumor growth in melanoma mouse models carrying a common cancer-driving mutation.26PubMed Central. Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth
A separate line of research exploits a basic physical property of cancer cell mitochondria: they carry a strongly negative electrical charge across their inner membrane, roughly negative 160 to negative 180 millivolts. This charge is often more extreme in cancer cells than in healthy cells, creating an opportunity for selective targeting. Positively charged molecules called triphenylphosphonium ions naturally accumulate inside mitochondria because they are drawn to the negative charge. When conjugated with anticancer drugs, these ions ferry the payload directly to cancer cell mitochondria, increasing the local drug concentration while reducing damage to normal tissue.27PubMed Central. Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy This approach has shown an ability to overcome resistance to conventional chemotherapy drugs that cancer cells normally pump out of their interior.28PubMed Central. Application Prospects of Triphenylphosphine-Based Mitochondria-Targeted Cancer Therapy More recent nanocarrier designs using triphenylphosphonium have aimed to reduce the required drug dose further while sparing healthy tissue.29PubMed Central. Triphenylphosphine-Based Mitochondrial Targeting Nanocarriers: Advancing Cancer Therapy
These mitochondria-targeted strategies are still largely in preclinical or early clinical stages, and none has yet become a standard cancer treatment. But the diversity of approaches under investigation, from metabolic inhibitors to nanocarrier-based drug delivery to strategies aimed at restoring mitochondrial function in exhausted immune cells, reflects a growing recognition that the organelle once dismissed as a simple battery is one of the most promising targets in oncology.
How Mitochondrial DNA Mutations Reshape the Tumor Immune Landscape
The relationship between mitochondrial DNA mutations and tumor immunity is more subtle than a simple “mutations cause cancer” story. Mitochondrial DNA mutations accumulate in tumors, and many have been documented across a wide range of cancer types.30PubMed Central. Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis But the functional consequences depend heavily on the fraction of a cell’s mitochondria carrying any given mutation, a concept known as heteroplasmy. As the breast cancer mouse study described earlier showed, moderate mutation loads promote aggressive tumors and metastasis, while very high loads actually impair growth. The mechanism behind this may involve how different mutation loads reprogram the immune environment: moderate mutations can enhance mitochondrial activity enough to generate signals that suppress immune attack, while extreme dysfunction may produce so much mitochondrial DNA leakage that it activates the cGAS-STING alarm too strongly for the tumor to suppress.14bioRxiv. MtDNA heteroplasmy controls tumor immune reprogramming through mitochondrial translation
This finding opens an interesting therapeutic question: could deliberately tipping a tumor’s mitochondrial DNA mutation load beyond the beneficial zone force it into a state where the immune system can regain the upper hand? The research is still early, but it hints at a counterintuitive strategy where worsening mitochondrial dysfunction in cancer cells, rather than trying to fix it, might expose the tumor to immune destruction. As each layer of mitochondrial biology in cancer gets better understood, the therapeutic puzzle grows both more complex and more rich with opportunity.